Final results from the first U.S. clinical study of a Cuban immunotherapy show that CIMAvax-EGF, a treatment targeting a particular cancer survival protein, epidermal growth factor, is safe and showed promising efficacy as part of a treatment combination with nivolumab (Opdivo) in patients with advanced non-small cell lung cancer.
Stand Up To Cancer is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors, such as osteosarcoma and mesothelioma.
Imvax Inc. announced positive results from an ongoing phase Ib clinical trial that demonstrate treatment with IGV-001, the company's novel autologous tumor cell vaccine, outperformed standard of care with prolonged overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme.
Astellas Pharma Inc. announced results from the phase III ADMIRAL clinical trial comparing Xospata (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
A study at MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma. Findings from the phase II trial were presented by study co-lead Nathan Fowler, associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.
The north-eastern region of the Islamic Republic of Iran has some of the highest rates of esophageal cancer anywhere in the world. New results from an international prospective study of 50,000 individuals, recently published online in the journal Gastroenterology, provide evidence on how the combined effects of six main risk factors are responsible for the high rates of esophageal cancer in this region.
In melanoma patients, taking over-the-counter probiotic supplements was associated with a 70% lower chance of response to cancer immunotherapy treatment with anti-PD-1 checkpoint inhibitors, according to a preliminary study from the Parker Institute for Cancer Immunotherapy and MD Anderson Cancer Center. The results were presented at the American Association for Cancer Research 2019 Annual Meeting in Atlanta.
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2- mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented at the AACR Annual Meeting 2019.
Women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs, compared with treatment with anastrozole alone, according to results of a SWOG Cancer Research Network study appearing in the New England Journal of Medicine.
A preclinical study led by scientists at the UCLA Jonsson Comprehensive Cancer Center suggests that heating solid tumors during CAR-T cell therapy can enhance the treatment's success.
